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Complex interplay between b-catenin signalling and
Notch effectors in intestinal tumorigenesis
Gre´gory Peignon,1,2 Aure´lie Durand,1,2 Wulfran Cacheux,1,2 Olivier Ayrault,3
Benoıˆt Terris,1,2 Pierre Laurent-Puig,4 Noah F Shroyer,5 Isabelle Van Seuningen,6
Tasuku Honjo,7 Christine Perret,1,2 Be´atrice Romagnolo1,2
ABSTRACT
Aims The activation of b-catenin signalling is a key step
in intestinal tumorigenesis. Interplay between the
b-catenin and Notch pathways during tumorigenesis has
been reported, but the mechanisms involved and the role
of Notch remain unclear.
Methods Notch status was analysed by studying
expression of the Notch effector Hes1 and Notch
ligands/receptors in human colorectal cancer (CRC) and
mouse models of Apc mutation. A genetic approach was
used, deleting the Apc and RBP-J or Atoh1 genes in
murine intestine. CRC cell lines were used to analyse the
control of Hes1 and Atoh1 by b-catenin signalling.
Results Notch signalling was found to be activated
downstream from b-catenin. It was rapidly induced and
maintained throughout tumorigenesis. Hes1 induction
was mediated by b-catenin and resulted from both the
induction of the Notch ligand/receptor and Notch-
independent control of the Hes1 promoter by b-catenin.
Surprisingly, the strong phenotype of unrestricted
proliferation and impaired differentiation induced by acute
Apc deletion in the intestine was not rescued by
conditional Notch inactivation. Hyperactivation of
b-catenin signalling overrode the forced differention
induced by Notch inhibition, through the downregulation
of Atoh1, a key secretory determinant factor downstream
of Notch. This process involves glycogen synthase kinase
3 b (GSK3b) and proteasome-mediated degradation. The
restoration of Atoh1 expression in CRC cell lines displaying
b-catenin activation was sufficient to increase goblet cell
differentiation, whereas genetic ablation of Atoh1 greatly
increased tumour formation in Apc mutant mice.
Conclusion Notch signalling is a downstream target of
b-catenin hyperactivation in intestinal tumorigenesis.
However, its inhibition had no tumour suppressor effect
in the context of acute b-catenin activation probably due
to the downregulation of Atoh1. This finding calls into
question the use of g-secretase inhibitors for the
treatment of CRC and suggests that the restoration of
Atoh1 expression in CRC should be considered as
a therapeutic approach.
INTRODUCTION
The Apc gene encodes a tumour suppressor linked to
80% of cases of sporadic colorectal cancer (CRC) and
involved in an inherited syndrome, familial adeno-
matous polyposis syndrome.1 We and others have
clearly shown that the inactivation of Apc is sufﬁ-
cient to initiate intestinal tumorigenesis.2 3 One of
the major effects of Apc loss is the aberrant activa-
tion of Wnt/b-catenin signalling. The stabilised
b-catenin is translocated to the nucleus, where it
forms a complex with Tcf/Lef transcription factors,
activating a genetic programme leading to an
imbalance between cell proliferation and differenti-
ation that triggers tumorigenesis.1
< Additional methods, figures
and a table are published online
only. To view these files please
visit the journal online (http://
gut.bmj.com).
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Significance of this study
What is already known about this subject?
< Inhibition of the Notch signalling pathway using
g-secretase inhibitors can force differentiation
of intestinal tumours induced by Apc loss into
goblet cells. Thereby, g-secretase inhibitors
have been proposed as a rationale for treatment
of intestinal cancers.
< Accordingly, interplay between the b-catenin
and Notch pathways during tumorigenesis has
been reported, but the mechanisms involved and
the role of Notch remain unclear.
What are the new findings?
< By analysing murine and human samples of all
steps of intestinal tumorigenesis, we found that
Notch signalling activation is an immediate effect
of Wnt/b-catenin deregulation and is maintained
throughout all the intestinal tumorigenesis.
< In addition, we showed that, in intestinal
tumorigenesis, the induction of Hes1 a well-
known Notch target gene, was mediated
directly by b-catenin signalling activation.
Thus, Hes1 expression results from both
a Notch-dependent and a Notch-independent
signalling in intestinal tumorigenesis.
< Surprisingly, the strong phenotype of unre-
stricted proliferation and impaired differentiation
induced by acute Apc deletion in the intestine
was not rescued by conditional Notch inactiva-
tion. Hyperactivation of b-catenin signalling
overrode the forced differentiation induced by
Notch inhibition, through the downregulation of
Atoh1, a key secretory determinant factor
downstream of Notch. This downregulation is
critical to the oncogenic outcome mediated by
b-catenin because it prevents the differentiation
of cancer cells.
How might it impact on clinical practice in the
foreseeable future?
< Our findings have important clinical implications,
as they call into question the utility of
g-secretase inhibitors as a treatment for
colorectal cancer and suggest that the stabilisa-
tion of Atoh1 may be of therapeutic importance.
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The Notch pathway is also known to be involved in the
control of cell fate choice between proliferation and differenti-
ation in intestinal epithelial lineages, and thus plays a major role
in intestinal homeostasis and tumorigenesis.1 The genes of the
Notch family encode transmembrane receptors. Interactions
between Notch receptors and Delta or Jagged ligands result in
a conformational change, followed by two proteolytic steps.
These cleavages release the Notch intracellular domain, which
forms a complex with the transcription factor RBP-J to activate
the transcription of downstream targets, such as the Hes1 gene.4
Loss-of-function studies have shown that Notch signalling
upregulates absorptive cell differentiation and downregulates
the differentiation of secretory lineages, including goblet cells,
Paneth cells and enteroendocrine cells.5 6 Cell fate seems to be
directly controlled by two main Notch target genes: Hes1,
a positive target, which stimulates the differentiation of
progenitors into absorptive enterocytes; and Atoh1, a negative
target gene that commits the progenitor to a secretory cell fate.
These studies, together with gain-of-function studies, have also
provided evidence that Notch signalling is required for the
maintenance of crypt progenitor cells in an undifferentiated and
proliferative state, suggesting a possible role in tumorigenesis.7e9
However, whereas Wnt/b-catenin signalling is well known to
play multiple roles in intestinal tumorigenesis, the role of Notch
in this process remains unclear.
We investigated the interplay between the Wnt/b-catenin and
Notch signalling pathways in intestinal tumorigenesis. We ﬁrst
evaluated Notch signalling status during intestinal tumorigen-
esis in humans and mice. We used several mouse models of Apc
mutation reproducing all steps of intestinal tumorigenesis, from
initiation to the more advanced stages, with the aim of deter-
mining when the Notch signalling pathway was activated
during this process. For studies of the impact of Notch signalling
during the intestinal tumorigenesis induced by Apc loss, we
simultaneously deleted both the Apc and RBP-J or Atoh1 genes
in the intestinal epithelium.
We found that Notch acted downstream from Wnt/b-catenin
at all stages of intestinal tumorigenesis and, surprisingly, that
Notch/RBP-J signalling was dispensable for the initiation of
b-catenin-mediated intestinal tumorigenesis. Our results indi-
cate that the inability of Notch/RBP-J inhibition to direct
differentiation was directly linked to post-transcriptional
control of Atoh1 by active b-catenin signalling. Finally, we found
that ablation of the Atoh1 gene strongly enhanced tumour
formation in Apc mutant mice. Thus, aberrant b-catenin
signalling has two main consequences in intestinal epithelial
cells: stimulation of the proliferation of stemcells andprogenitors,
and inhibition of their differentiation.
MATERIALS AND METHODS
Collection of samples from patients
Colorectal adenocarcinomas and corresponding normal tissue
samples were collected at the Hotel-Dieu and Cochin Hospitals
(France). The tissue samples were obtained with informed,
written consent from the patients and the approval of the local
ethics committee. A tissue microarray containing 55 colon
adenocarcinomas was analysed with a microarrayer (Beecher
Instruments, Wisconsin, USA).
Figure 1 Induction of Hes1 expression in human and murine intestinal
carcinogenesis. Analysis of Hes1 mRNA levels by quantitative reverse
transcriptionePCR (RTePCR) in human colorectal cancer (CRC) and in
normal tissue (A). Immunostaining for Hes1 and b-catenin in human CRC
and in normal tissue (B). Scale bars, 200 mm. Analysis of Hes1
expression by quantitative RTePCR (C) and immunohistochemistry (D)
in normal tissue and adenomas from APC+/ mice.
(continued)
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Animal generation
All experiments involving mice were carried out in accordance
with French government regulations. Mice were housed in
conventional conditions. The generation of mutant mice and
treatments are described in the supplementary material.
Histology, immunohistochemistry and in situ hybridisation
For histological, immunohistochemical and in situ hybridisation
methods, see the supplementary materials and Supplementary
table 1.
Molecular and biochemical analyses
Detailed descriptions of procedures are provided in the supple-
mentary material.
In silico promoter analysis
For the identiﬁcation of phylogenetically conserved Tcf-binding
sites, the Hes1 59-ﬂanking regions were analysed with Gene2-
Promoter, DiAlign TF and MatInspector software from the
Genomatix database.
Statistical analysis
The signiﬁcance of the differences observed was assessed with
the non-parametric Wilcoxon matched-pairs test for human
samples and two-tailed Student t tests for mouse samples and in
vitro experiments. Detailed descriptions are provided in the
supplementary materials.
RESULTS
Hes1 expression during human and murine intestinal
tumorigenesis
We assessed the potential role of Notch signalling in human
CRC by ﬁrst investigating the expression of Hes1, a well-known
Notch target gene, in 14 random CRC cases and in patient-
matched normal tissues, by quantitative reverse tran-
scriptionePCR (RTePCR). Most of the adenocarcinomas had
signiﬁcantly higher levels of Hes1 mRNA than the matched
colon samples (ﬁgure 1A). Consistent with this ﬁnding, immu-
nohistochemical studies of human adenocarcinomas showed
strong nuclear staining for both b-catenin and Hes1 (ﬁgure 1B).
We extended our analysis of Hes1 expression in murine
adenomas developed spontaneously in Apc+/ mice.10 We also
observed signiﬁcantly higher levels of Hes1 mRNA and strong
nuclear expression of Hes1 in murine adenomas (ﬁgure 1C,D).
These observations suggest that Notch signalling is activated
throughout intestinal tumorigenesis, in both humans and mice.
Mutational analyses of the Notch genes in human CRC
One possible mechanism of Hes1 induction during oncogenesis
is the occurrence of activating mutations in Notch receptors.
Such mutations were ﬁrst described in the Notch1 gene in Tcell
acute lymphoblastic leukaemia.11 They affect the intracellular
heterodimerisation domain and/or the C-terminal PEST domain
of Notch1. We carried out a sequencing analysis to search for
such somatic mutations in the Notch1, 2, 3 and 4 genes in 19
CRCs and patient-matched normal tissues (Supplementary
ﬁgure 1 online). We found no such point mutations in any of the
CRCs analysed (data not shown).
Loss of Apc results in the induction of Notch signalling
components
We investigated the mechanism underlying abnormal Hes1
expression in CRC further by studying expression of the various
ligands and receptors involved in Notch signalling. We observed
Figure 2 Induction of Notch receptors and ligands in human and
murine intestinal carcinogenesis. Fold change in mRNA levels for
the Notch receptors and ligands, as measured by quantitative
reverse transcriptionePCR (RTePCR), in comparisons of human
colorectal carcinomas with normal tissue (A). In situ hybridisation
of Notch2 and Delta4 in human normal colon and in colorectal cancer
(B). Quantitative RTePCR analyses of mRNA levels for the Notch
receptors and ligands in normal tissues and adenomas from APC+/
mice (C).
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no signiﬁcant expression of Dll1, Dll3 and Notch3 in normal
tissue or tumours (data not shown). However, quantitative
RTePCR showed that levels of Dll4, Jag1, Jag2, Notch1 and
Notch2 mRNA were higher in human adenocarcinomas than in
normal tissue (ﬁgure 2A). Thus, three of the ﬁve ligands tested
and two of the four receptors tested were induced in human
CRC. We then carried out in situ hybridisation for Notch2 and
Dll4 on a cohort of 55 CRC samples on a tissue microarray. We
observed weak expression of Notch2 and Dll4 in normal colon
and the overexpression of both probes in many adenocarcinomas.
Notch2 was moderately and strongly induced in 49% and
29% of CRCs, respectively, and Dll4 was slightly and actively
induced in 30% and 47%, respectively (ﬁgure 2B). However, we
found no link between the expression levels of the Notch2 and
Dll4 genes in tumours, suggesting that stochastic events may
determine the level of expression of these genes. Quantitative
RTePCR also showed an upregulation of Notch ligands and
receptors in murine adenomas from Apc+/ mice (ﬁgure 2C).
We then investigated whether the deregulation of Notch
signalling occurred early in b-catenin-induced intestinal tumori-
genesis, by analysing Hes1 expression in a conditional mouse
model with acute APC loss in the adult intestinal epithelium
(Apclox/loxVil-CreERT2).3 In this system, Apc was deleted in
response to tamoxifen injection (Apc-null mice, Apc/). This
system is highly efﬁcient, with almost 100% recombination of
the target allele in the small intestine of adult mice and a rapid
loss of Apc function.3 This genetic deletion system did not mimic
the stochastic process of tumour initiation occurring in Apc+/
mice, but it did reproduce all the phenotypes previously identiﬁed
as associated with early intestinal lesions. As previously reported,
5 days after tamoxifen injection, considerable enlargement of the
crypt compartment, with intense cell proliferation, apoptosis and
severe defects in differentiation, was observed in the intestine of
mutant mice.3 This enlargement was accompanied by Hes1
induction, at both the mRNA and protein levels (ﬁgure 3AeC).
Accordingly, we observed nuclear staining for Hes1 in all
dysplastic cells with nuclear b-catenin, consistent with Apc loss
(ﬁgure 3C). This increase in Hes1 expression could result from
hyperactive b-catenin signalling or it could occur because of an
expansion of cells that normally express Hes1. To distinguish
between these two hypotheses, we analysed Hes1 expression
in a human CRC cell line in which hyperactive b-catenin
signalling was blocked. SW480 cells, which produce a truncated
form of APC that cannot target b-catenin for degradation,
were transfected with two different small interfering RNAs
(siRNAs) targeting b-catenin. We found that Hes1 expression
was markedly decreased by b-catenin depletion (ﬁgure 3D).
Thus, the expression of Hes1, a Notch downstream effector,
increases strongly and rapidly in response to the b-catenin
activation induced by Apc loss in the intestine. Notch signalling
pathway activation is therefore an early, downstream event in
Wnt/b-catenin-induced intestinal tumorigenesis.
b-Catenin activation promotes both direct and indirect
regulation of Notch signalling
We then investigated the mechanism by which Wnt/b-catenin
signalling might control Hes1 expression. Two possible
Figure 3 Hes1 expression is correlated with Wnt/b-catenin signalling.
Quantitative reverse transcriptionePCR (RTePCR) analysis of Hes1
mRNA levels in control and APC/ mice 5 days after tamoxifen injection
(A). Immunoblot analyses of Hes1 levels in three different samples from
control and APC/ mice (day 5) (B), and Hes1 and b-catenin levels in
SW480 cells after transfection with two small interfering RNAs (siRNAs)
against b-catenin or scramble siRNA (D). b-Actin levels were used for
normalisation. Immunohistochemistry studies of Hes1 and b-catenin in
control and APC/ mice (day five) (C). Scale bars, 50 mm.
(continued)
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mechanisms were considered: an indirect mechanism involving
the activation of Notch signalling partners and a direct mecha-
nism in which b-catenin/Tcf controls the activity of the Hes1
promoter.
Consistent with the indirect mechanism, we observed
a strong increase in the expression of Dll4, Jag1 and Jag2, and the
Notch1, Notch2 and Notch4 receptors 5 days after Apc loss
(ﬁgure 4A). We determined the mRNA levels of these genes
before and after siRNA-mediated b-catenin downregulation in
SW480 cells. Consistent with previous reports, we found that
b-catenin depletion signiﬁcantly inhibited only Jag1 expression
(Supplementary ﬁgure 2).12 This suggests that except for Jag1
induction, the increase expression of the others ligands and the
Notch receptors observed rapidly after Apc loss is not direct. An
expansion of the crypt progenitor zone induced by Apc loss as an
alternative explanation for the apparent increase in expression of
Notch ligands and receptors could not be excluded. However, the
fact that some of the ligands/receptors were strongly induced in
human CRC by in situ hybridisation does not support this
hypothesis.
In addition, Genomatix software identiﬁed two conserved
Tcf-binding sites in the Hes1 promoter, close to the canonical
RBP-J-binding site. The conservation of these sites across species
supports the hypothesis that they are functionally relevant
(ﬁgure 4B). We performed luciferase reporter assays in SW480
cells to evaluate the activity of the human Hes1 promoter
(Hes-2.5 and Hes-0.4 constructs) containing both the Tcf- and
proximal RBP-J-binding sites. We also used the Hes-0.4-RBP-J
(Hes-mutRBP) construct, which contains only the Tcf sites, the
RBP-J-binding sites being mutated (ﬁgure 4B). As expected, the
activation of Notch signalling by the human Notch intracellular
domain induced a strong increase only in Hes-2.5 and Hes-0.4
promoter activities (ﬁgure 4C). However, similar basal levels of
promoter activitywere observed for theHes-0.4 andHes-mutRBP
promoters, this activity being independent of the activation
of Notch signalling (ﬁgure 4D). As these constructs contained
two conserved Tcf-binding sites, the basal promoter activity
observed may be linked to the aberrant Wnt/b-catenin signalling
pathway. We tested this hypothesis, by analysing the effect of
a dominant-negative form of Tcf4, DNTCF4. DNTCF4 induced
a decrease in basal promoter activity for all constructs, whether or
not they contained a functional RBP-J-binding site (ﬁgure 4E).
These ﬁndings are consistent with direct control of the Hes1
promoter by Wnt/b-catenin signalling through the conserved Tcf
motifs, independently of Notch activation. They are also
supported by a recent genome-wide ChIP-on-chip analysis, which
identiﬁed the Hes1 promoter region as a target of Tcf4.13
Thus, the induction of the downstream Notch target Hes1 in
Wnt/b-catenin-mediated intestinal tumorigenesis results from
two complementary processes. One is Notch dependent and
Figure 4 The Hes1 promoter is regulated byWnt/b-catenin signalling through conserved Tcf motifs. Quantitative reverse transcriptionePCR (RTePCR)
analysis of mRNA levels for the Notch receptors and ligands in control and APC/ mice (day 5) (A). Conserved Tcf-binding element motifs identified by
Genomatix software in the proximal region of the Hes1 promoter of several species. The putative Tcf- and RBP-J-binding sites are represented by blue
and purple boxes, respectively. Maps of the constructs used to study the transcriptional activity of the Hes1 promoter in SW480 cells. Different
fragments of regulatory sequences flanking the human Hes1 promoter (Hes-2.5, Hes-0.4 and Hes-mutRBP constructs) were fused with the luciferase
gene. The Hes-mutRBP construct contains only the Tcf sites, the RBP-J-binding sites having been mutated (B). All the constructs were used to transfect
SW480 cells together with the Notch1 intracellular domain (NICD), the dominant-negative form of Tcf4 (DNTCF4) or empty vector (control) (CeE).
170 Gut 2011;60:166e176. doi:10.1136/gut.2009.204719
GI cancer
 group.bmj.com on January 4, 2011 - Published by gut.bmj.comDownloaded from 
involves deregulated expression of Notch ligands and receptors.
The other is Notch independent and involves direct control of
the Hes1 promoter by Wnt/b-catenin signalling, via the
conserved Lef/Tcf sites.
RBP-J deficiency does not alter the immediate phenotype
of Apc deficiency in vivo
Wnt/b-catenin and Notch cooperate during intestinal tumori-
genesis,7 9 12 and our results indicate that Notch acts
downstream from the Wnt cascade. We assessed the contribu-
tion of Notch signalling to the phenotype associated with Apc
loss in the intestine (Apc-null mice, Apc/), by simultaneously
deleting the RBP-J and Apc genes in the intestinal epithelium
(double-mutant mice, Apc/RBP/).3 14 We chose to study the
RBP-J gene, to avoid possible redundancy in the functions of
Notch receptors. Based on previous published results obtained
with g-secretase inhibitors,7 we assumed that the inhibition of
Notch signalling would, at least partly, rescue the defects
Figure 5 Loss of RBP-J does not alter the cell differentiation defects of Apc-deficient cells. KaplaneMeier survival analysis of control (purple), APC/
(green) and APC/RBP/ mice (red) (injections are indicated by an arrow) (A). Representative H&E-stained sections of control, APC/ and APC/
RBP/mice 5 days after tamoxifen (Tam) injection (day 5) (B). PCR of DNA extracted from intestines of control and APC/RBP/mice showing the
excision of the floxed RBP-J alleles (day 5) (C). Quantitative reverse transcriptionePCR (RTePCR) analysis of Atoh1, p27kip1 and p57kip2 mRNA levels in
control, APC/ and APC/RBP/ mice (day 5) (D). Immunoblot analyses of Hes1 levels in three different samples from control, APC/, RBP/ and
APC/RBP/ mice (day 5) (E). b-Actin levels were used for normalisation. Alcian blue staining for control, APC/, RBP/ and APC/RBP/ mice
(F). Quantitative RTePCR analysis of Muc2, Gob4 and Gob5 mRNA levels in control, APC/, RBP/ and APC/RBP/ mice (day 5) (G). For
statistical analyses mutant mice were compared with control mice. Scale bars, 100 mm.
Gut 2011;60:166e176. doi:10.1136/gut.2009.204719 171
GI cancer
 group.bmj.com on January 4, 2011 - Published by gut.bmj.comDownloaded from 
induced by Apc loss: the increase in cell proliferation and the
decrease in goblet cell differentiation.
Surprisingly, on day 5 after the ﬁrst injection, we found no
difference in survival between thedouble-mutant (Apc/RBP/)
and the Apc-null mice. Both the double-mutant and the Apc-null
mice became ill and 100% of themice died within 7e8 days of the
tamoxifen injection (ﬁgure 5A). No major histological difference
was observed between the small intestines of the single- and
double-mutant mice (ﬁgure 5B).
We checked that the Notch pathway was truly inactivated in
the intestine of the double-mutant mice, by showing that efﬁ-
cient recombination of the ﬂoxed RBP-J alleles had occurred after
tamoxifen injection (ﬁgure 5C). We also analysed the expression
of Notch target genes. Notch downregulates Atoh1 and the
cyclin-dependent kinase inhibitors, p27kip1 and p57kip2.6 15
Quantitative RTePCR experiments showed the level of expres-
sion of the Atoh1, p27kip1 and p57kip2 genes to be speciﬁcally
increased in double-mutant mice (ﬁgure 5D). The persistence of
Hes1 expression in the double-mutantmice is consistent with the
role of Wnt/b-catenin signalling activation in the regulation of
Hes1 expression (ﬁgure 5E,4E). Moreover, this underlines the
complex regulation of Atoh1 by Hes1 and suggests that other
factors are present to remove the repression of Atoh1 expression
following RBP deletion. Our ﬁndings conﬁrmed that the recom-
bined RBP-J allele was a true null allele and that inhibition of the
Notch/RBP-J pathway in the double-mutant mice was effective.
Numerous reports have indicated that the inhibition of Notch
signalling leads to forced differentiation into secretory lineages,
Figure 6 Loss of RBP-J does not
affect the increase in cell proliferation in
Apc-deficient cells. Analyses of cell
proliferation by immunohistochemistry
(A). Bromodeoxyuridine (BrdU),
phosphorylated histone H3 (pH3) and
Ki-67 staining was performed on control,
APC/ and APC/RBP/ mice,
5 days after tamoxifen (Tam) injection.
Quantification of BrdU- and pH3-positive
cells per crypt in control, APC/ and
APC/RBP/ mice (B). Scale bars,
100 mm. Quantitative reverse
transcriptionePCR (RTePCR) analyses
of mRNA for various cell cycle
components in control, APC/ and
APC/RBP/ mice (day 5). For
statistical analyses, mutant mice were
compared with control mice (C).
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due to Atoh1 overexpression, resulting in the large-scale
conversion of progenitor cells into postmitotic goblet cells.7 15
Apc loss has also been shown to lead to an ampliﬁcation of
multipotent progenitor cells associated with a defect in goblet
cell differentiation.2 3 16 We investigated whether the RBP-J
ablation associated with Atoh1 mRNA upregulation could
rescue the differentiation defects resulting from Apc loss in the
intestine. Histological analyses showed that this was not the
case. H&E and Alcian blue staining revealed that double-mutant
animals displayed an abnormal depletion of mature goblet cells
similar to that observed in the Apc-null mice (ﬁgure 5B,F). We
carefully examined the expression of several markers speciﬁc to
goblet cells (Muc2, Gob4 and Gob5), comparing the results with
those for RBP single-mutant mice (RBP/ mice). Six days after
tamoxifen injection, quantitative RTePCR experiments showed
an increase in their level of expression speciﬁcally in the RBP/
mice (ﬁgure 5G). Our results therefore suggest that in the
context of acute Wnt/b-catenin activation, Notch inhibition
cannot direct terminal differentiation into goblet cells.
We then analysed the effect of RBP-J gene deletion on the cell
proliferation defects induced by acute Apc loss. Histological
analysis showed that the morphological architecture of the
small intestine of double-mutant mice was indistinguishable
from that of Apc-null mice (ﬁgure 5B). Gross changes associated
with Apc deﬁciency, such as enlarged and aberrant crypts, were
observed in the double-mutant mice. We further investigated
proliferation status in the double-mutant and Apc-null mice. We
assessed levels of bromodeoxyuridine (BrdU) incorporation, and
staining for phosphophorylated histone H3 and Ki-67 in double-
mutant mice and Apc-null mice, 6 days after tamoxifen injec-
tions (ﬁgure 6A,B). Ki-67 staining and the numbers of cells in the
S and M phases were similar in Apc mutant mice and double-
mutant mice. This suggests that RBP-J loss neither delays nor
directly affects the cell cycle in the context of Apc loss.
Consistent with this ﬁnding, all the cell cycle regulators affected
by Apc loss were similarly deregulated in the double-mutant
intestine (ﬁgure 6C). The increase in p27kip1 and p57kip2 levels
(ﬁgure 5D) resulting from Notch inhibition could not overcome
the unrestricted proliferation induced by the aberrant activation
of Wnt/b-catenin signalling.
As observed for the proliferation defect, Notch inhibition due
to RBP-J loss had no effect on the apoptotic response to Apc loss
in the intestine (ﬁgure 7A).
Finally, we examined the crypt stem cell population, as these
cells have been clearly identiﬁed as the initial source of intestinal
cancer.17 We used quantitative RTePCR to analyse the expres-
sion of several stem cells markers, such as Lgr5, Ascl2, Musashi-1
and Sox9. No difference in stem cell ampliﬁcation was observed
between Apc-null and double-mutant mice (ﬁgure 7B).
The inhibition of Notch/RBP-J signalling therefore had no
major impact on the early and severe phenotypes induced by
Apc loss in the intestine. This suggests that the Notch pathway
is dispensable, at least for the initiation of Wnt/b-catenin-
induced intestinal tumorigenesis.
Post-transcriptional downregulation of Atoh1 by the activation
of b-catenin signalling
Next, we searched for a mechanism which could link the absence
of an integrative effect between the Notch inhibition and the
Wnt activation in the initiation of intestinal tumorigenesis. One
possible explanation is that acute Wnt/b-catenin signalling could
modulate a downstream component of Notch. Importantly, it
was shown by Watanabe’s group that Atoh1 protein is degraded
by the Wnt/b-catenin signalling in CRC cell lines.18 19 They
showed that Atoh1 protein is targeted by proteasome-mediated
degradation via its phosphorylation by glycogen synthase kinase
3b (GSK3b). This was an attractive explanation to support our
data. However, in this study, the mechanism of Atoh1 expression
stabilisation was based on a forced expression of an Atoh1-tag
plasmid. In the current study, we pursued the analysis of Atoh1
expression in three CRC cell lines by analysing the effect of
GSK3b or proteasome inhibitors on the endogeneous Atoh1
protein level. First, we conﬁrmed that a forced expression of Tag-
Atoh1-HA-tag plasmid was decreased by the oncogenic activa-
tion of b-catenin signalling in HEK-293Tcells (ﬁgure 8A). We thus
analysed the activity of the endogenous Atoh1 after treatment
with GSK3b or proteasome inhibitors (AR-A014418 andMG132)
in SW480, TC7 and HT29 colon cancer cells, three cell lines
displaying constitutive activation of b-catenin signalling. The
lack of an efﬁcient Atoh1 antibody led us to test this hypothesis
with a reporter construct relaying Atoh1 activity. In previous
studies, Atoh1 was reported to act in a self-regulatory manner, by
binding to an enhancer region containing an E-box site conserved
between mice and humans and located in the 39-untranslated
sequence.20 We used a plasmid encoding luciferase under the
control of the Atoh1 enhancerepromoter regulatory sequences
(Enh-Atoh1-Luc) for transfection analyses. We found that the
treatment of SW480, HT29 and TC7 cells with GSK3b or
Figure 7 Loss of RBP-J does not affect the stem cell amplification or
apoptosis induced by Apc deficiency. Identification of apoptotic cells in
control, APC/ and APC/RBP/ mice, 5 days after tamoxifen (Tam)
injection, by the deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) method (A). Scale bars, 100 mm. Quantitative reverse
transcriptionePCR (RTePCR) analyses of mRNA levels for stem cell
markers in control, APC/ and APC/RBP/ mice (day 5). For
statistical analyses, mutant mice were compared with control mice (B).
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proteasome inhibitors increased Atoh1-mediated transcription
(ﬁgure 8B).We then analysed the effect of GSK3b and proteasome
inhibitors on goblet cell differentiation. Previous studies have
shown a direct transactivation of theMuc2 promoter by Atoh1.21
As expected, treatment with GSK3b or proteasome inhibitors
increased the activity of the Muc2 promotereluciferase reporter
construct (Muc2-Luc) in all CRC cell lines tested (ﬁgure 8C).
In accordance with the observations of Watanabe’s group,
these results suggest that the aberrant activation of b-catenin
signalling leads to Atoh1 degradation in CRC cell lines and that
GSK3b or proteasome inhibitors can force the expression of
Atoh1 required to drive goblet cell differentiation. They indicate
that Atoh1 stabilisation is a critical event in the conversion of
b-catenin-activated intestinal epithelial cells into goblet cells.
Atoh1 loss enhances the tumour formation induced by Apc loss
Loss of differentiation is frequently observed during cancer
progression and then master regulators of differentiation may be
key regulators of tumour formation. In this light, a previous
study indicated that mosaic deletion of Atoh1 in the colon
increased the number of polyps that developed in ApcMin/+ mice
of 5 months of age.22 That study utilised a constitutive Cre
transgene driven by the intestine-speciﬁc fatty acid-binding
protein promoter.23 Here, we pursued this study by using the
Villin Cre transgene inducible by tamoxifen (VilCreERT2) which
is highly efﬁcient throughout the small and the large intestinal
epithelium, and we have analysed the early effect of Atoh1
deletion in the context of heterozygous Apc deletion. For this,
we generated double-mutant mice (Atoh1lox/lox; Apclox/+
VilCreERT2) and compared the intestinal lesions developed in
these mice with those developed in control mice (Apclox/+
VilCreERT2) 3 weeks after tamoxifen injection (Apc+/eAtoh1/
vs Apc+/e).23 We checked, by PCR analysis, that tamoxifen
injections induced efﬁcient recombination of the ﬂoxed Atoh1
and Apc alleles (data not shown). As expected, Atoh1 deletion
led to complete ablation of the secretory lineages in both the
Figure 8 b-Catenin signalling controls
Atoh1 expression post-transcriptionally.
Co-transfections of HEK-293T cells with
various amounts of plasmid encoding
Atoh1-haemagglutinin (HA) (0, 50 and
150 ng) and an oncogenic mutant form
of b-catenin (0 and 500 ng). Atho1
protein levels were analysed by
immunoblotting of the HA tag and
quantified by Genetool from SynGene
software (A). b-Actin levels were used
for normalisation. Analyses of Atho1
and Muc2 transcriptional activity in
SW480, TC7 and HT-29 cells by
transfection with plasmids encoding
luciferase under the control of the Atoh1
(Enh-Atoh1-Luc) or Muc2 regulatory
sequences (Muc2-Luc). Cells were
treated with glycogen synthase kinase 3
b (GSK3b) inhibitor (AR-A014418) for
48 h or with proteasome inhibitor
(MG132) for 18 h before the
quantification of luciferase activity (B).
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small and large intestine. Lysosyme and Alcian blue staining
indicated a complete loss of Paneth cells and goblet cells
throughout the intestine (ﬁgure 9A). In addition, all Apc+/
Atoh1/ mice developed a large number of early adenomas,
within 3 weeks, in both the small and large intestine, whereas
only rare lesions were observed in Apc+/ mice (ﬁgure 9B,C).
Thus, the absence of Atoh1 rapidly promotes the development
of intestinal tumours induced by Apc loss. Atoh1 acts as
a master gene that instructs cell fate commitment in secretory
lineages and acts as a brake on oncogenic process throughout the
whole intestinal tract.
DISCUSSION
Several recent studies have suggested that the Wnt and Notch
pathways cooperate to trigger intestinal tumorigenesis.7 9 12
However, the molecular mechanism involved in this cross-talk
remains unclear. We have shown that Notch activation, as
reﬂected by overproduction of the Hes1 and Notch ligands and
receptors, is a frequent and early event in Wnt-induced intestinal
tumorigenesis, and that this activation is maintained
throughout tumorigenesis and downstream from the Wnt/b-
catenin cascade. We show that Hes1 overexpression in intestinal
cancer results from two complementary processes controlled by
b-catenin. One is the b-catenin-mediated upregulation of the
ligands and receptors of the Notch pathway, as previously
described.9 12 24 However, among all the Notch ligands and
receptors tested, only the expression of Jag1 appears directly
affected by b-catenin activation. The upregulation of the other
members appears to be an indirect consequence of the activation
of the b-catenin signalling. The second process is a direct
increase in Hes1 promoter activity mediated by b-catenin/Tcf
signalling. Indeed, although Hes1 is a genuine Notch effector, it
may also be activated by other signalling pathways, such as
those of Wnt, Sonic Hedgehog, IkBa and Ras/MAPK.25e28
Altogether, we and others showed a complex integration of
the Wnt and Notch pathways in intestinal epithelial cells.
During intestine development, it has been shown that the
effects of Notch signalling on intestinal cell proliferation are
dependent on Wnt. This epistatic study indicates that Notch
acts upstream of Wnt. However, in adult intestine, during
Apc-driven tumorigenesis, our data indicate that activation of
Notch acts downstream of Wnt. This statement is in accordance
with other published data.12 29 Altogether, it appears that the
interaction between the Wnt and the Notch pathways is
complex and appears to be context dependent.
We analysed the role of Notch in tumorigenesis, by assessing
the effect of blocking Notch signalling in cells in which
b-catenin was deregulated, mimicking the early stage of
tumorigenesis. We used conditional targeting methods to delete
the Apc and RBP-J genes simultaneously in the intestinal
epithelium of adult mice. As the treatment of ApcMin adenomas
with g-secretase inhibitors led to the conversion of some
adenoma cells to goblet cells,7 we expected to alter the initiation
of tumour development induced by acute Apc loss. However,
Notch inhibition did not rescue the severe phenotype caused by
Apc loss in the intestine. No commitment to goblet cell lineage
differentiation was observed, and unrestricted proliferation,
with enlarged, highly proliferative crypts and stem cell ampliﬁ-
cation was seen in all cases, regardless of Notch status. Based on
published data, one possible explanation is that acute Wnt/b-
catenin signalling could modulate expression of Atoh1, a down-
stream component of Notch.18 19 Using CRC cell lines, we
showed that endogenous Atoh1 protein levels were down-
regulated by Wnt/b-catenin signalling. The stabilisation of
Atoh1 protein by GSK3b and proteasome inhibitors allowed the
expression of the goblet cell marker. Conversely, we showed that
genetic ablation of Atoh1 dramatically accelerated in 3 weeks
the emergence of Apc-mediated adenomas throughout the
whole small and large intestine (results of this study,22).
Figure 9 Loss of Atoh1 enhances the tumour formation induced by
Apc loss. Alcian blue staining and immunostaining for lysosyme in
Apc+/ and Apc+/Atoh1/ mice (A). Mean number of lesions
per animal in the small intestine and colon of Apc+/ (n¼5) and
Apc+/Atoh1/ (n¼7) mice (B). H&E staining and immunostaining for
b-catenin in Apc+/Atoh1/ mice (C).
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Consistent with the tumour suppressor role of Atoh1 in CRCs,
recent studies have reported the epigenetic and genetic silencing
of the Atoh1 gene in human CRC.22 These results highlight
a critical role for Atoh1 in the oncogenic effect of b-catenin
signalling in intestinal tumorigenesis.
Our data contrast with those of a study reporting the
conversion of adenoma cells into goblet cells after the treatment
of ApcMin mice with g-secretase inhibitors.7 However, conver-
sion to goblet cells was nonetheless relatively rare. Almost 50%
of adenomas showed no conversion of tumours cell and only
28% displayed the conversion of 1e10% of tumour cells into
goblet cells.7 There may be several reasons for the discrepancies
between these two studies. As Notch inactivation was achieved
by deletion of the RBP gene or with g-secretase inhibitors, we
cannot exclude the possibility of an RBP-independent effect of
Notch.30 However, it is more likely that the different effects of
Notch inhibition on the Apc-mediated phenotype are linked to
different b-catenin activation thresholds. Indeed, a dose-depen-
dent effect of b-catenin has already been described.31 32 Based on
the expression proﬁle of the b-catenin target gene c-myc that we
have previously described,3 10 it appears that the level of acti-
vation of Wnt/b-catenin signalling differs between the two
mouse models. Strong and homogeneous b-catenin activation
probably leads to Atoh1 destabilisation in the presence of
a conditional homozygous deletion of Apc, whereas the hetero-
geneous b-catenin activation in ApcMin mice may allow Notch
inhibition by maintaining Atoh1 levels above a threshold sufﬁ-
cient to induce goblet differentiation, in a subset of cells. A recent
study showed that the complete deletion of Atoh1 abolished the
effects of g-secretase inhibitors on cancerous intestinal cells.33
Our data highlight the complex interplay between the Wnt
and Notch signalling pathways during intestinal tumorigenesis.
Two main Notch effectors are controlled in opposite ways by
the Wnt/b-catenin pathway. Hes1 is transcriptionally upregu-
lated, whereas Atoh1 is post-transcriptionally downregulated.
This downregulation is critical to the oncogenic outcome
mediated by b-catenin, because it prevents the differentiation of
cancer cells. Our ﬁndings have important clinical implications,
as they call into question the utility of g-secretase inhibitors as
a treatment for CRC and suggest that the stabilisation of Atoh1
may be of therapeutic importance.
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